Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation
Europace · 2024
DOI: 10.1093/europace/euae054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2024. Verfasst von Akash Fichadiya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Libin Cardiovascular Institute, Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, T2N 4N1, C…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Atrial Fibrillation, Sodium-Glucose Transporter 2 Inhibitors, Ischemic Attack, Transient. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Kidney Disease Network, Interdisciplinary Chronic Disease Collaboration.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Prior studies suggest that sodium–glucose cotransporter-2 inhibitors (SGLT2is) may decrease the incidence of atrial fibrillation (AF). However, it is unknown whether SGLT2i can attenuate the disease course of AF among patients with pre-existing AF and Type II diabetes mellitus (DM). In this study, our objective was to examine the association between SGLT2i prescription and arrhythmic outcomes among patients with DM and pre-existing AF. Methods and results We conducted a population-based cohort study of adults with DM and AF between 2014 and 2019. Using a prevalent new-user design, individuals prescribed SGLT2i were matched 1:1 to those prescribed dipeptidyl peptidase-4 inhibitors (DPP4is) based on time-conditional propensity scores. The primary endpoint was a composite of AF-related healthcare utilization (i.e. hospitalization, emergency department visits, electrical cardioversion, or catheter ablation). Secondary outcome measures included all-cause mortality, heart failure (HF) hospitalization, and ischaemic stroke or transient ischaemic attack (TIA). Cox proportional hazard models were used to examine the association of SGLT2i with the study endpoint. Among 2242 patients with DM and AF followed for an average of 3.0 years, the primary endpoint occurred in 8.7% (n = 97) of patients in the SGLT2i group vs. 10.0% (n = 112) of patients in the DPP4i group [adjusted hazard ratio 0.73 (95% confidence interval 0.55–0.96; P = 0.03)]. Sodium–glucose cotransporter-2 inhibitors were associated with significant reductions in all-cause mortality and HF hospitalization, but there was no difference in the risk of ischaemic stroke/TIA.
Conclusion
Among patients with DM and pre-existing AF, SGLT2is are associated with decreased AF-related health resource utilization and improved arrhythmic outcomes compared with DPP4is.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Libin Cardiovascular Institute, Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, T2N 4N1, Calgary, AB, Canada.
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB, Canada.
- O'Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB, Canada.
- Department of Medicine, University of Alberta, 13-103 Clinical Sciences Building, 11350 - 83 Avenue NW, T6G 2G3 Edmonton, AB, Canada.
- Department of Medicine, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, T2N 4N1 Calgary, AB, Canada.
ORCID-Profile: Amity Quinn, Flora Au, Dennis Campbell, Darren Lau, Paul Ronksley, Reed Beall, David J T Campbell, Derek S Chew
Förderung
- Alberta Kidney Disease Network
- Interdisciplinary Chronic Disease Collaboration
Zitieren
APA
Fichadiya, A., Quinn, A., Au, F., Campbell, D., Lau, D., Ronksley, P., Beall, R., Campbell, D. J. T., Wilton, S. B., & Chew, D. S. (2024). Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation. Europace. https://doi.org/10.1093/europace/euae054
Vancouver
Fichadiya A, Quinn A, Au F, Campbell D, Lau D, Ronksley P, et al. Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation. Europace. 2024. doi:10.1093/europace/euae054
BibTeX
@article{Fichadiya2024,
author = {Fichadiya, Akash and Quinn, Amity and Au, Flora and Campbell, Dennis and Lau, Darren and Ronksley, Paul and Beall, Reed and Campbell, David J T and Wilton, Stephen B and Chew, Derek S},
title = {Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation},
journal = {Europace},
year = {2024},
doi = {10.1093/europace/euae054}
}
EUVIMED